TP53 and cancer: We then sought to identify if the gained and lost peaks overlap with the known binding sites of mutant p53 (inferred from previous ChIP-Seq analysis in cancer cell lines) [14, 15] or predicted to have wild-type p53 response elements (RE) [19], both canonical and non-canonical (see Methods) (Fig. 1e, f).